Satellos Bioscience (NASDAQ:MSLE) Issues Earnings Results, Misses Expectations By $0.11 EPS

Satellos Bioscience (NASDAQ:MSLE) issued its quarterly earnings results on Friday. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.11), Zacks reports.

Satellos Bioscience Price Performance

NASDAQ:MSLE opened at $6.19 on Friday. The stock has a market capitalization of $95.70 million, a P/E ratio of -3.99 and a beta of 1.10. Satellos Bioscience has a 12-month low of $4.53 and a 12-month high of $13.39.

Analysts Set New Price Targets

A number of brokerages have commented on MSLE. Cantor Fitzgerald began coverage on Satellos Bioscience in a research report on Wednesday, March 11th. They issued an “overweight” rating for the company. Wall Street Zen cut Satellos Bioscience to a “strong sell” rating in a research report on Saturday, March 14th. Zacks Research upgraded Satellos Bioscience to a “hold” rating in a research note on Tuesday, February 10th. Finally, Weiss Ratings initiated coverage on Satellos Bioscience in a research report on Wednesday, February 11th. They issued a “sell (d-)” rating for the company. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold”.

About Satellos Bioscience

Satellos Bioscience Inc is a regenerative medicine company dedicated to developing novel therapeutics which stimulate or restore muscle regeneration in severe disorders. The company’s lead program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy. Satellos Bioscience Inc, formerly known as iCo Therapeutics Inc, is based in Toronto, Ontario.